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INTRODUCTION
Adiponectin is an adipose tissue-derived plasma protein that plays an important role in energy homeostasis regulation, glucose and lipid metabolism as well as anti-inflammatory responses in the vascular system (Hu et al., 1996; . Low plasma adiponectin concentrations are linked to type 2 diabetes (T2D) (Weyer et al., 2001) , obesity and coronary heart disease (CHD) related traits ( Matsuda et al., 2002; Kumada et al., 2003) . Possible mechanisms of adiponectin action in relation with these inflammatory diseases may include its inhibition of smooth muscle cell proliferation, monocyte adhesion to endothelium, and macrophage uptake of LDL (Chen et al., 2005) .
Adiponectin is a product of the ADIPOQ gene consisting of three exons that occupies 16 kb on chromosome 3q27. During the last five years, a large number of association studies have been performed to search for polymorphisms that may influence metabolic conditions (reviewed in Vasseur et al. (2006) and Menzaghi et al. (2007) ). Even though the number of polymorphisms and haplotypes are repeatedly associated with increased or decreased blood adiponectin levels Mackevics et al., 2006; Li et al., 2007; Kyriakou et al., 2008) , association analysis of these SNPs PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 63 (2009 ), No. 4/5 (663/664), pp. 174-179. DOI: 10.2478 
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The aim of our study was to search for the association between systematically selected adiponectin gene polymorphisms and T2D, body mass index (BMI) as well as CHD phenotypes in the Latvian population.
MATERIALS AND METHODS
Study subjects. The study was based on data and samples from the Genome Data Base of Latvian Population, the disease based biobank. Briefly: participating individuals were over the age of 18; the health status was recorded, the diagnoses were based on approved clinical criteria according to the ICD-10 codes (International Classification of Diseases); andanthropometric measurements (including weight and stature), ethnic, social, environmental information and familial health status was acquired based on a self-reported questionnaire. Written informed consent was obtained from all participants. The study group for the subsequent genotyping of selected markers was selected from all available subjects with validated health records and questionnaires in the biobank. We excluded patients with diseases where outcome or treatment may influence BMI, including all types of cancer and diseases of the thyroid gland, but not excluding patients with cardiovascular diseases. All patients with T2D were included in the study. In total, 835 subjects were selected based on these criteria. The study protocol was approved by the Central Medical Ethics Committee of Latvia. SNP genotyping. TagSNPs in the adiponectin gene locus were selected using Haploview software (Barrett et al., 2005) . The SNPs with previously published effect on adiponectin plasma concentration were force included in the tagSNP set. MALDI TOF-based genotyping platform (Bruker Daltonics) was used for genotyping all SNPs (primer sequences and reaction conditions available upon request). Genotype calling and quality control was performed using GenoTools software (Bruker Daltonics).
Statistical analysis.
Statistical analyses were performed with the PLINK 1.06 software (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007) . In contrast to the natural BMI values, the logarithmically transformed BMI values displayed normal distribution and were further used for all quantitative analyses. Linear regression was applied to examine the association between tagSNPs and log-BMI adjusting for age and gender. The allelic association test (additive model), dominant and recessive model analysis was performed using the exact Fisher's test. Logistic regression analysis adjusting for age and those factors that showed significant association with trait under multivariate logistic regression analysis were used for dichotomous trait analysis. Bonferroni correction was used to adjust for multiple testing. The permutation test was performed using label-swapping between SNP and trait condition or logBMI values but leaving intact correlation with other covariates. 10,000 permutations were performed for each analysis and corrected (EMP2) P-values were used. These values are corrected based on calculation of the proportion of permutations in which any of the test statistics exceeds the particular observed statistic and are more stringent then uncorrected P-values. Odds ratios (OR) and CI (95%) values were obtained from logistic regression analysis (Exp(B) value), unadjusted mean logBMI values were calculated and back-transformed for each genotype.
RESULTS
Description of the study group is summarised in Table 1 . A total of ten SNPs in the adiponectin gene locus were genotyped in all or part of the participants. SNP information, observed minor allele frequency (MAF) and results of deviation from the Hardy-Weinberg equilibrium test are shown in Table 2 . None of the SNPs were in disagreement with Hardy-Weinberg equilibrium after correction for multiple testing. The exact number of successfully genotyped samples for each SNP in the study group is displayed in Tables  3 and 4 This association remained significant after applying the permutation test (P = 0.049), but lost its significance after correction for multiple comparisons. Neither of the SNPs showed any association with T2D when tested using logistic regression with adjustment for age, sex and BMI under different genetic models (Table 3) . Similarly, no difference in mean values of logBMI was found between genotypes of any SNP included in analysis (Table 4) . We also tested for association of SNPs with other traits present in our study group. The results are shown in Figure 1A . Allele A of SNP rs182052 was less frequent in patients with myocardial infarction (39%) compared to controls (45%). This association remained significant using multiple logistic regression analysis adjusting for sex, age, BMI and T2D (P = 0.02; OR = 0.76, CI95%[0.61-0.92]). The permutation test on this SNP gave a corrected P value of 0.028. The association did not retain its significance after Bonferroni correction.
In order to identify possible effects of individual haplotypes on traits analysed in our study we performed haplotypebased association. In total, 14 haplotypes were reconstructed with frequency exceeding 1%. Statistical analysis of the distribution of probabilistically-inferred set of haplotypes for different traits is shown in Figure 1B . Haplotype determined by C and A alleles of rs1501299 and rs3774261, respectively, and common alleles for other SNPs was more frequent (26%) in patients with atrial fibrillation compared to others (14%), P = 0.009.
DISCUSSION
We report in this study the first evaluation of adiponectin gene polymorphisms in relation with T2D, BMI and cardiovascular traits in the Latvian population. a-Distribution of subjects according to genotypes/models: additive 22/12/11; dominant: 12+22/11; recessive 22/12+11 (1, common allele; 2, rare allele) b-From logistic regression analysis adjusted for gender, age and logBMI order to ensure maximal capture of all known alleles. In addition, the forced inclusion of variants shown to influence plasma adiponectin levels was performed. Estimated minor allele frequencies (Table 2 ) of all ten SNPs were higher than 0.05 in the Latvian population and similar to those reported in the SNP database (www.ncbi.nlm.nih.gov/SNP) or other publications . We believe that altogether this ensures the high informativeness of the selected set of ten markers.
In the present quantitative trait analysis we found no evidence for an association of the tested SNPs with changes in BMI value. Other studies have previously reported that at least three of the SNPs also included in this study (rs266729, rs2241766, rs1501299) might modulate body weight (reviewed in Vasseur et al. (2006) ). However, recent meta-analysis did not confirm the association of these or other markers with BMI (Menzaghi et al., 2007) . The failure to identify a stable association between ADIPOQ polymorphisms and BMI, despite the repeatedly confirmed relationship between the levels of plasma adiponectin and BMI (Yang et al., 2001; Spranger et al., 2003) , can be explained by the variation in genetic background determining the predisposition to obesity. Stratification of the study group based on common genetic variants influencing body mass regulation could help to estimate the role of adiponectin SNPs more precisely.
The only SNP that was significantly associated with T2D in our study was rs2241766, under the recessive genetic model. The relatively low frequency of this SNP and absence of GG homozygotes in the control group, however, do not allow to precisely determine the relative risk of this variation. G allele of rs2241766 was found to be associated with decreased levels of serum adiponectin (Xita et al., 2005; Li et al., 2007; ) as well as T2D (Li et al., 2007) . This result is in agreement with finding, that low plasma levels are associated with insulin resistance and T2D. It should be noted, however, that a substantial number of studies failed to replicate these results Potapov et al. Szopa et al., 2009) . Since previous studies did not support the recessive model for association of rs2241766 with T2D our result may be as well a false positive finding.
Adiponectin mediates vascular inflammation as an inhibitor of smooth muscle cell proliferation and macrophage uptake and has been associated with decreased risk of hypertension (Iwashima et al., 2004) , miocardial infarction (Pischon et al., 2004) and ischemic stroke (Chen et al., 2005) . We, therefore, tested the association of all SNPs analysed with presence of different cardiovascular traits. In our study, rs182052 was associated with decreased risk of miocardial infarction. Allele A of rs182052 was previously associated with a decreased adiponectin serum level Kyriakou et al., 2008) and, thus, would be expected to have negative effect on cardiovascular functions which is opposite to our finding. Nevertheless, Hegener et al. (2006) reported a decreased risk of ischemic stroke for carriers of this allele. One of the imputed haplotypes was found to be more frequent in another heart disease trait, atrial fibrillation. To our knowledge this is the first report of genetic variants of adiponectin associated with this trait. The two SNPs, rs1501299 and rs3774261, determining this haplotype, have been associated with increased adiponectin level Kyriakou et al., 2008) . Interestingly, plasma adiponectin is higher in patients with persistent atrial fibrillation (Shimano et al., 2008) , which is in opposite to the general tendency of a high adiponectin level being protective to most of the CHD-related pathogeneses. Similarly, high blood adiponectin was found to be a predictor for mortality in heart failure (Chang et al., 2009) . It has been speculated that this could be explained with lower sensitivity of adiponectin receptors in atrial fibrillation resulting in increased adiponectin secretion (Shimano et al., 2008) . In general, however, the situation with CHD and adiponectin polymorphisms is similar to obesity and T2D, where associations found in some studies can not be consistently replicated in other studies (Menzaghi et al., 2007; Vasseur et al., 2006) . It should also be mentioned that none of the genome wide association studies have identified the ADIPOQ locus as a candidate for any trait (based on a database search at https://gwas.lifesciencedb.jp and http://www.genome.gov/gwastudies/).
The main drawback of our study is an increased proportion of patients with metabolic and cardiovascular traits in study group. The relatively low number of healthy participants in the study may have increased Type II error, which would mask some existing association or decrease the statistical power. From this respect, additional study with a large control group is needed to fully evaluate the impact of adiponectin polymorphisms on T2D and BMI in the Latvian population. An important problem in all studies on a large number of genetic variations is multiple testing. In our study, none of the discovered associations retained its significance (P < 0.05) after applying the Bonferroni test. It has been suggested, however, that study-wide adjustments are not appropriate in the context of genetic association analysis and that permutation based significance testing can be used instead. All associations found in this study remained significant after the permutation test.
In summary, although adiponectin plasma levels are linked with many metabolic traits, our study does not provide strong support for the hypothesis that SNPs in the ADIPOQ locus play an important role in development of T2D, obesity and CHD.
